Anti-clotting prospect most important for Lilly, report says

A drug Eli Lilly and Co. is developing to prevent blood clots is the most important in Lilly’s pipeline, according to a report on TheStreet.com this morning.

Prasugrel, which aims to prevent heart attacks and strokes, faces important clinical trials this year, and could yield several billion dollars in sales.

However, its impact on the Indianapolis drugmaker will be tempered by having to share revenue with Daiichi Sankyo, the Japanese company co-developing the drug.